Ligand requirements for involvement of PKCε in synergistic analgesic interactions between spinal μ and δ opioid receptors

British Journal of Pharmacology

Volumn 172, Issue 2, 2015, Pages 642-653

  Schuster, D J ^a   Metcalf, M D ^b   Kitto, K F ^a   Messing, R O ^c   Fairbanks, C A ^a,d   Wilcox, George L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

biased agonism; heterodimer; heteromer; intrathecal; PKC ; spinal; synergy; opioid receptor; opioid receptor

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; BETA ENDORPHIN; DELTA OPIATE RECEPTOR AGONIST; DELTORPHIN; DELTORPHIN 1; DELTORPHIN I; DELTORPHIN II; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; LEUCINE ENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR AGONIST; OPIATE AGONIST; OXYCODINDOLE; OXYMORPHINDOLE; PROTEIN KINASE C EPSILON; UNCLASSIFIED DRUG; DELTA OPIATE RECEPTOR; DELTORPHIN I, ALA(2)-; DELTORPHIN II, ALA(2)-; LIGAND; MORPHOLINE DERIVATIVE; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; OLIGOPEPTIDE;

ADULT; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; FEMALE; HOT WATER TAIL FLICK TEST; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TAIL FLICK TEST; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEAT; KNOCKOUT MOUSE; METABOLISM; PAIN; PROTEIN MULTIMERIZATION; SPINAL CORD;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HOT TEMPERATURE; LIGANDS; MALE; MICE, KNOCKOUT; MORPHINE; MORPHOLINES; OLIGOPEPTIDES; PAIN; PROTEIN KINASE C-EPSILON; PROTEIN MULTIMERIZATION; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; SPINAL CORD;

EID: 84920163132     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12774     Document Type: Article

References (59)

1. Abul-Husn NS, Sutak M, Milne B, Jhamandas K, (2007). Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists. Br J Pharmacol 151: 877-887.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., CGTP Collaborators. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1562.
3. Bao L, Jin SX, Zhang C, Wang LH, Xu ZZ, Zhang FX, et al. (2003). Activation of delta opioid receptors induces receptor insertion and neuropeptide secretion. Neuron 37: 121-133.
4. Beaudry H, Dubois D, Gendron L, (2011). Activation of spinal mu- and delta-opioid receptors potently inhibits substance P release induced by peripheral noxious stimuli. J Neurosci 31: 13068-13077.
5. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT, (1999). Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286: 2495-2498.
6. Bohn LM, Lefkowitz RJ, Caron MG, (2002). Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 22: 10494-10500.
7. Borgland SL, Connor M, Osborne PB, Furness JB, Christie MJ, (2003). Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem 278: 18776-18784.
8. Cahill CM, White TD, Sawynok J, (1996). Synergy between mu/delta-opioid receptors mediates adenosine release from spinal cord synaptosomes. Eur J Pharmacol 298: 45-49.
9. Cahill CM, Morinville A, Lee MC, Vincent JP, Collier B, Beaudet A, (2001). Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. J Neurosci 21: 7598-7607.
10. Chou WH, Wang D, McMahon T, Qi ZH, Song M, Zhang C, et al. (2010). GABAA receptor trafficking is regulated by protein kinase C(epsilon) and the N-ethylmaleimide-sensitive factor. J Neurosci 30: 13955-13965.
11. Clark MJ, Emmerson PJ, Mansour A, Akil H, Woods JH, Portoghese PS, et al. (1997). Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor. J Pharmacol Exp Ther 283: 501-510.
12. Costantino CM, Gomes I, Stockton SD, Lim MP, Devi LA, (2012). Opioid receptor heteromers in analgesia. Expert Rev Mol Med 14: e9.
13. Cox BM, Christie MJ, Devi L, Toll L, Traynor JR, (2015). Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol 172: 317-323.
14. Csukai M, Chen CH, De Matteis MA, Mochly-Rosen D, (1997). The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase Cepsilon. J Biol Chem 272: 29200-29206.
15. Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS, (2005). Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A 102: 19208-19213.
16. Fairbanks CA, (2003). Spinal delivery of analgesics in experimental models of pain and analgesia. Adv Drug Deliv Rev 55: 1007-1041.
17. Fairbanks CA, Wilcox, GL, (1999). Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. J Pharmacol Exp Ther 290: 403-412.
18. Fan T, Varghese G, Nguyen T, Tse R, O'Dowd BF, George SR, (2005). A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem 280: 38478-38488.
19. Gendron L, Lucido AL, Mennicken F, O'Donnell D, Vincent JP, Stroh T, et al. (2006). Morphine and pain-related stimuli enhance cell surface availability of somatic delta-opioid receptors in rat dorsal root ganglia. J Neurosci 26: 953-962.
20. Gendron L, Esdaile MJ, Mennicken F, Pan H, O'Donnell D, Vincent JP, et al. (2007). Morphine priming in rats with chronic inflammation reveals a dichotomy between antihyperalgesic and antinociceptive properties of deltorphin. Neuroscience 144: 263-274.
21. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, et al. (2000). Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 275: 26128-26135.
22. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA, (2000). Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci 20: RC110.
23. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA, (2004). A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A 101: 5135-5139.
24. Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E, et al. (2010). Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 3: ra54.
25. He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB, et al. (2011). Facilitation of mu-opioid receptor activity by preventing delta-opioid receptor-mediated codegradation. Neuron 69: 120-131.
26. Hylden JL, Wilcox GL, (1980). Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67: 313-316.
27. Janssen PA, Niemegeers CJ, Dony JG, (1963). The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawl reflex in rats. Arzneimittelforschung 13: 502-507.
28. Joseph EK, Levine JD, (2010). Mu and delta opioid receptors on nociceptors attenuate mechanical hyperalgesia in rat. Neuroscience 171: 344-350.
29. Khasar SG, Lin YH, Martin A, Dadgar J, McMahon T, Wang D, et al. (1999). A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron 24: 253-260.
30. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
31. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
32. Metcalf MD, Yekkirala AS, Powers MD, Kitto KF, Fairbanks CA, Wilcox GL, et al. (2012). The delta opioid receptor agonist SNC80 selectively activates heteromeric mu-delta opioid receptors. ACS Chem Neurosci 3: 505-509.
33. Miaskowski C, Sutters KA, Taiwo YO, Levine JD, (1992). Antinociceptive and motor effects of delta/mu and kappa/mu combinations of intrathecal opioid agonists. Pain 49: 137-144.
34. Mittal N, Tan M, Egbuta O, Desai N, Crawford C, Xie CW, et al. (2012). Evidence that behavioral phenotypes of morphine in beta-arr2-/- mice are due to the unmasking of JNK signaling. Neuropsychopharmacology 37: 1953-1962.
35. Morinville A, Cahill CM, Esdaile MJ, Aibak H, Collier B, Kieffer BL, et al. (2003). Regulation of delta-opioid receptor trafficking via mu-opioid receptor stimulation: evidence from mu-opioid receptor knock-out mice. J Neurosci 23: 4888-4898.
36. Ossipov MH, Lopez Y, Bian D, Nichols ML, Porreca F, (1997). Synergistic antinociceptive interactions of morphine and clonidine in rats with nerve-ligation injury. Anesthesiology 86: 196-204.
37. Ossipov MH, Suarez LJ, Spaulding TC, (1989). Antinociceptive interactions between alpha2-adrenergic and opiate agonists at the spinal level in rodents. Anesth Analg 68: 194-200.
38. Overland AC, Kitto KF, Chabot-Dore AJ, Rothwell PE, Fairbanks CA, Stone LS, et al. (2009). Protein kinase C mediates the synergistic interaction between agonists acting at alpha2-adrenergic and delta-opioid receptors in spinal cord. J Neurosci 29: 13264-13273.
39. Patwardhan AM, Berg KA, Akopain AN, Jeske NA, Gamper N, Clarke WP, et al. (2005). Bradykinin-induced functional competence and trafficking of the delta-opioid receptor in trigeminal nociceptors. J Neurosci 25: 8825-8832.
40. Pradhan AA, Smith ML, Kieffer BL, Evans CJ, (2012). Ligand-directed signalling within the opioid receptor family. Br J Pharmacol 167: 960-969.
41. Raehal KM, Bohn LM, (2011). The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 60: 58-65.
42. Riedl MS, Schnell SA, Overland AC, Chabot-Dore AJ, Taylor AM, Ribeiro-da-Silva A, et al. (2009). Coexpression of alpha 2A-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn. J Comp Neurol 513: 385-398.
43. Rowan MP, Ruparel NB, Patwardhan AM, Berg KA, Clarke WP, Hargreaves KM, (2009). Peripheral delta opioid receptors require priming for functional competence in vivo. Eur J Pharmacol 602: 283-287.
44. Rozenfeld R, Devi LA, (2007). Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J 21: 2455-2465.
45. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, O'Donnell D, et al. (2009). Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 137: 1148-1159.
46. Schramm CL, Honda CN, (2010). Co-administration of delta- and mu-opioid receptor agonists promotes peripheral opioid receptor function. Pain 151: 763-770.
47. Schuster DJ, Kitto KF, Overland AC, Messing RO, Stone LS, Fairbanks CA, et al. (2013). Protein kinase C{epsilon} is required for spinal analgesic synergy between delta opioid and alpha-2a adrenergic receptor agonist pairs. J Neurosci 33: 13538-13546.
48. Shin SW, Eisenach JC, (2003). Intrathecal morphine reduces the visceromotor response to acute uterine cervical distension in an estrogen-independent manner. Anesthesiology 98: 1467-1471. discussion 1466A.
49. Sutters KA, Miaskowski C, Taiwo YO, Levine JD, (1990). Analgesic synergy and improved motor function produced by combinations of mu-delta- and mu-kappa-opioids. Brain Res 530: 290-294.
50. Sweitzer SM, Wong SM, Peters MC, Mochly-Rosen D, Yeomans DC, Kendig JJ, (2004). Protein kinase C epsilon and gamma: involvement in formalin-induced nociception in neonatal rats. J Pharmacol Exp Ther 309: 616-625.
51. Tallarida R, Murray R, (1987). Manual of Pharmacological Calculations with Computer Programs. Springer: New York.
52. Tallarida RJ, (2002). The interaction index: a measure of drug synergism. Pain 98: 163-168.
53. Tallarida RJ, Porreca F, Cowan A, (1989). Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci 45: 947-961.
54. Wang HB, Zhao B, Zhong YQ, Li KC, Li ZY, Wang Q, et al. (2010). Coexpression of delta- and mu-opioid receptors in nociceptive sensory neurons. Proc Natl Acad Sci U S A 107: 13117-13122.
55. Yekkirala AS, Kalyuzhny AE, Portoghese PS, (2010). Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective mu-delta agonists. ACS Chem Neurosci 1: 146-154.
56. Yekkirala AS, Kalyuzhny AE, Portoghese PS, (2013). An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands. ACS Chem Biol 8: 1412-1416.
57. Zhao B, Wang HB, Lu YJ, Hu JW, Bao L, Zhang X, (2011). Transport of receptors, receptor signaling complexes and ion channels via neuropeptide-secretory vesicles. Cell Res 21: 741-753.
58. Zheng H, Chu J, Zhang Y, Loh HH, Law PY, (2011). Modulating micro-opioid receptor phosphorylation switches agonist-dependent signaling as reflected in PKCepsilon activation and dendritic spine stability. J Biol Chem 286: 12724-12733.
59. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, et al. (1999). Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24: 243-252.